polyneuropathy associated with IgM monoclonal gammapathy with anti-MAG
diseaseOn this page
Also known as anti-MAG neuropathyneuropathy associated with monoclonal IgM antibodies to myelin-associated glycoprotein
Summary
polyneuropathy associated with IgM monoclonal gammapathy with anti-MAG (MONDO:0018977) is a disease and 5 clinical trials. Top therapeutic interventions include rituximab. A subtype of acquired peripheral neuropathy — broader associated-gene and molecular evidence is on the parent page (see Disease family below).
At a glance
- Clinical trials: 5
Clinical features
No curated clinical features (Orphanet) for this disease.
Identifiers
Disease identifiers
| Field | Value |
|---|---|
| Canonical name | polyneuropathy associated with IgM monoclonal gammapathy with anti-MAG |
| Mondo ID | MONDO:0018977 |
| Orphanet | 639 |
| UMLS | C1736154 |
| MedGen | 1434346 |
| GARD | 0013173 |
| Is cancer (heuristic) | no |
Also known as: anti-MAG neuropathy · neuropathy associated with monoclonal IgM antibodies to myelin-associated glycoprotein
Disease family
Classification path: disease › human disease › disease by body system or component › nervous system disorder › peripheral nervous system disorder › peripheral neuropathy › acquired peripheral neuropathy › polyneuropathy associated with IgM monoclonal gammapathy with anti-MAG
Related subtypes (11): axonal polyneuropathy associated with IgG/IgM/IgA monoclonal gammopathy, cranial neuralgia, neuralgic amyotrophy, POEMS syndrome, non-recovering obstetric brachial plexus lesion, anterior cutaneous nerve entrapment syndrome, pudendal neuralgia, multifocal motor neuropathy, CANOMAD syndrome, simple cryoglobulinemia, radiation-induced plexopathy
Genetics & variants
GWAS landscape
No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.
Variant details and genetic-evidence tiers
No tiered GWAS variants or ClinVar records for this disease.
Genes & proteins
No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).
Function
No pathway enrichment — requires an associated-gene cohort.
Therapeutics
No druggable-target or therapeutic data for this disease’s cohort.
Clinical trials & evidence
Clinical trials
Clinical trials: 5.
Phase distribution (across all retrieved trials)
| Phase | Trials |
|---|---|
| Not specified | 2 |
| PHASE3 | 1 |
| PHASE2 | 1 |
| PHASE1/PHASE2 | 1 |
Top trials by phase / activity
| NCT | Phase | Status | Title |
|---|---|---|---|
| NCT05136976 | PHASE3 | RECRUITING | Rituximab Therapy in Anti-Myelin Associated Glycoprotein Patients With Characteristics of Good Responders |
| NCT02967679 | PHASE2 | COMPLETED | SERENDEM : MD1003 in Patients Suffering From Demyelinating Neuropathies, an Open Label Pilot Study |
| NCT04568174 | PHASE1/PHASE2 | TERMINATED | First in Human Study to Test the Safety and Preliminary Efficacy of PPSGG in Patients With Anti-MAG Neuropathy |
| NCT07461896 | Not specified | RECRUITING | Studying Nerve Function and Structure in Charcot-Marie-Tooth Disease, Anti-MAG Neuropathy and CIDP |
| NCT03397303 | Not specified | COMPLETED | Quantification of Nerve Stiffness in Neuropathies |
Drugs tested across these trials (top 30)
| Molecule | Max phase | Trials referencing |
|---|---|---|
| RITUXIMAB | 4 | 1 |
Related Atlas pages
- Drugs: Rituximab